Trending NewsTrending NewsNASDAQ:ALKS Alkermes (ALKS) Stock Price, News & Analysis $27.14 +0.14 (+0.51%) As of 10:28 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Alkermes Stock (NASDAQ:ALKS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alkermes alerts:Sign Up Key Stats Today's Range$26.67▼$27.5950-Day Range$26.13▼$31.7152-Week Range$25.56▼$36.45Volume184,424 shsAverage Volume1.77 million shsMarket Capitalization$4.47 billionP/E Ratio12.93Dividend YieldN/APrice Target$40.92Consensus RatingModerate Buy Company Overview Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Read More Alkermes Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreALKS MarketRank™: Alkermes scored higher than 96% of companies evaluated by MarketBeat, and ranked 50th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAlkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAlkermes has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alkermes' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth4.58% Earnings GrowthEarnings for Alkermes are expected to grow by 4.58% in the coming year, from $1.31 to $1.37 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 12.92, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.89.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 12.92, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.19.Price to Earnings Growth RatioAlkermes has a PEG Ratio of 1.60. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 2.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.52% of the float of Alkermes has been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Alkermes has recently increased by 12.31%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.17 Percentage of Shares Shorted7.52% of the float of Alkermes has been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Alkermes has recently increased by 12.31%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.81 News SentimentAlkermes has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Alkermes this week, compared to 8 articles on an average week.Search Interest11 people have searched for ALKS on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.MarketBeat Follows2 people have added Alkermes to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $210,143.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alkermes' insider trading history. Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address ALKS Stock News HeadlinesAlkermes plc (NASDAQ:ALKS) Q2 2025 Earnings Call Transcript1 hour ago | msn.comAlkermes Q2 Sales Up 14 PercentJuly 30 at 5:14 AM | theglobeandmail.comA $674B Industry Missed the Bigger PictureTV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.July 30 at 2:00 AM | Mode Mobile (Ad)Needham & Company LLC Reaffirms Buy Rating for Alkermes (NASDAQ:ALKS)July 30 at 3:03 AM | americanbankingnews.comAlkermes plc (ALKS) Q2 2025 Earnings Call TranscriptJuly 29 at 3:03 PM | seekingalpha.comAlkermes plc Reports Second Quarter 2025 Financial ResultsJuly 29 at 7:00 AM | prnewswire.comAlkermes plc (NASDAQ:ALKS) Receives $40.92 Consensus Price Target from AnalystsJuly 27 at 2:55 AM | americanbankingnews.comAlkermes Announces Positive Phase 2 Study ResultsJuly 24, 2025 | theglobeandmail.comSee More Headlines ALKS Stock Analysis - Frequently Asked Questions How have ALKS shares performed this year? Alkermes' stock was trading at $28.76 at the beginning of 2025. Since then, ALKS stock has decreased by 6.1% and is now trading at $27.00. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) issued its earnings results on Tuesday, July, 29th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.10. The company's revenue was down 2.1% on a year-over-year basis. Read the conference call transcript. Is Alkermes doing a stock buyback? Alkermes' Board of Directors approved a stock buyback program on Thursday, February 15th 2024, which allows the company to buy back $400,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 8.2% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's management believes its shares are undervalued. Does Alkermes have any subsidiaries? Alkermes subsidiaries include Rodin Therapeutics. Who are Alkermes' major shareholders? Top institutional investors of Alkermes include Atle Fund Management AB (0.14%), TD Asset Management Inc (0.13%), Aberdeen Group plc (0.11%) and Wedge Capital Management L L P NC (0.08%). Insiders that own company stock include Christian Todd Nichols, Craig C Hopkinson, Cato T Laurencin and Nancy Wysenski. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings7/29/2025Today7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:ALKS CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees1,800Year Founded1987Price Target and Rating Average Price Target for Alkermes$40.92 High Price Target$52.00 Low Price Target$26.00 Potential Upside/Downside+51.5%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$2.09 Trailing P/E Ratio12.92 Forward P/E Ratio20.61 P/E Growth1.6Net Income$367.07 million Net Margins23.30% Pretax Margin27.90% Return on Equity27.52% Return on Assets17.98% Debt Debt-to-Equity RatioN/A Current Ratio3.33 Quick Ratio2.92 Sales & Book Value Annual Sales$1.51 billion Price / Sales2.94 Cash Flow$2.74 per share Price / Cash Flow9.86 Book Value$9.05 per share Price / Book2.98Miscellaneous Outstanding Shares164,901,000Free Float157,645,000Market Cap$4.45 billion OptionableOptionable Beta0.44 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ALKS) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredOne stock to replace Nvidia"I said 'SELL' before this stock dropped 90%. Today, I'm shouting 'BUY NOW' before it's too late." In 2000,...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thNew China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.